For the Inventor, By the Inventor

Enter assignee name

Dublin, Ireland

Nogra Pharma Limited

USPTO Granted Patents = 53

% Expired Patents = 41.5

CIPO Patents = 3

EPO Patents = 20

Trademarks = 13

Forward Citations = 572

Loading Chart...

Loading Chart...

15 inventors (with patents filed for the assignee):

Francesca Viti (29 out of 29 patents)

Sergio Baroni (26 out of 46 patents)

Salvatore Bellinvia (25 out of 27 patents)

4. Giovanni Monteleone (20 out of 23 patents)

5. Giancarlo Naccari (7 out of 10 patents)

6. Salvatore Demartis (5 out of 5 patents)

7. Marie McNulty (3 out of 3 patents)

8. Alice Tomei (2 out of 6 patents)

9. Peter Buchwald (2 out of 4 patents)

10. Daan Hommes (2 out of 2 patents)

11. Auke Verhaar (2 out of 2 patents)

12. Gijs Van Den Brink (2 out of 2 patents)

13. Luca Inverardi (2 out of 9 patents)

14. Antonello Pileggi (2 out of 5 patents)

15. Camillo D Ricordi (2 out of 26 patents)

Core Competencies:

Aryl Receptor Modulators

Fibrosis Treatment

Antisense Oligonucleotides

T-Cell Modulation

Diabetes Therapies

PPAR Receptors

EGF Receptors

Colorectal Cancer

Lactose Intolerance

Hair Related Conditions

Inflammatory Bowel Disease

Colon Carcinogenesis

53 patents: Sort by Forward Citations

1. 12577256 - ARYL RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME (2026-03-17),

2. 12509416 - Process of making 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof (2025-12-30),

3. 12291494 - Methods of treating fibrosis (2025-05-06),

4. 12071623 - IL-34 antisense agents and methods of using same (2024-08-27),

5. 12012418 - Aryl receptor modulators and methods of making and using the same (2024-06-18),

6. 11905232 - Process of making 3-(4′-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof (2024-02-20),

7. 11753365 - Methods of treating fibrosis (2023-09-12),

8. 11427600 - Aryl receptor modulators and methods of making and using the same (2022-08-30),

9. 11162097 - Methods of treating intestinal fibrosis using SMAD7 inhibition (2021-11-02),

10. 11046641 - Methods of treating fibrosis (2021-06-29),

11. 10959970 - Methods of treating hair related conditions (2021-03-30),

12. 10738309 - Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field (2020-08-11),

13. 10633660 - Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field (2020-04-28),

14. 10562883 - Heterocycles capable of modulating T-cell responses, and methods of using same (2020-02-18),

15. 10473669 - Methods for treating inflammatory bowel disease (2019-11-12),

Company Overview

Nogra Pharma Limited, based in Dublin, Ireland, specializes in pharmaceutical research with a focus on innovative therapies for various medical conditions. The company is engaged in the development of advanced treatments, including aryl receptor modulators and antisense oligonucleotides, targeting areas such as fibrosis, diabetes, and colorectal cancer. Nogra's research also encompasses T-cell modulation and the exploration of PPAR and EGF receptors, aiming to address significant unmet medical needs through cutting-edge scientific advancements.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

53 Patents

#36 in Dublin

#62 in Ireland

#13,348 in the World

Dublin, Ireland

Nogra Pharma Limited

Forward Citations = 572

15 inventors:

Francesca Viti (29 out of 29 patents)

Sergio Baroni (26 out of 46 patents)

Salvatore Bellinvia (25 out of 27 patents)

4. Giovanni Monteleone (20 out of 23 patents)

5. Giancarlo Naccari (7 out of 10 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Nogra Pharma Limited. Retrieved from https://idiyas.com/company/nogra-pharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…